ERBB2 and non-small cell lung carcinoma: The present study aimed to evaluate the genomic and immune characteristics of NSCLC patients with EGFR or HER2 exon 20 mutations from a large dataset with molecular spectrum, tumor mutational burden (TMB), PD‐L1 expression, the CD4+ and CD8+ tumor‐infiltrating lymphocytes (TILs) infiltration, as well as the efficacy of immune checkpoint inhibitor and TKIs.